ResMed (RMD) – Investment Analysts’ Weekly Ratings Updates

ResMed (NYSE: RMD) recently received a number of ratings updates from brokerages and research firms:

  • 11/2/2026 – ResMed was downgraded by Canaccord Genuity Group from “buy” to “hold”.
  • 10/30/2026 – ResMed had its “hold” rating reaffirmed by Needham & Company LLC.
  • 10/30/2026 – ResMed was given a new $270.00 price target by Mizuho.
  • 10/30/2026 – ResMed had its price target raised by Citigroup from $240.00 to $270.00. They now have a “neutral” rating on the stock.
  • 10/30/2026 – ResMed had its price target raised by Wells Fargo & Company from $215.00 to $250.00. They now have an “equal weight” rating on the stock.
  • 10/30/2026 – ResMed had its price target raised by Royal Bank Of Canada from $262.00 to $288.00. They now have an “outperform” rating on the stock.
  • 10/30/2026 – ResMed had its price target raised by KeyCorp from $267.00 to $277.00. They now have an “overweight” rating on the stock.
  • 10/13/2026 – ResMed was given a new $240.00 price target by Mizuho.
  • 10/8/2026 – ResMed was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.

ResMed Trading Down 0.7%

Shares of NYSE RMD opened at $240.85 on Friday. ResMed Inc. has a 12-month low of $180.26 and a 12-month high of $277.67. The company has a current ratio of 2.65, a quick ratio of 1.88 and a debt-to-equity ratio of 0.04. The stock’s 50 day simple moving average is $233.55 and its 200 day simple moving average is $224.05. The company has a market cap of $33.88 billion, a price-to-earnings ratio of 21.94, a price-to-earnings-growth ratio of 1.47 and a beta of 0.77.

ResMed (NYSE:RMD – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.67 by $0.24. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.39 billion. ResMed had a net margin of 27.79% and a return on equity of 26.42%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 earnings per share. Equities research analysts expect that ResMed Inc. will post 12.14 EPS for the current year.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Shareholders of record on Thursday, November 12th will be paid a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 12th. ResMed’s payout ratio is presently 24.04%.

Insider Activity

In other ResMed news, General Counsel Michael Rider sold 400 shares of the company’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $255.00, for a total value of $102,000.00. Following the completion of the transaction, the general counsel owned 12,318 shares in the company, valued at approximately $3,141,090. This represents a 3.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter Farrell sold 970 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $234.73, for a total transaction of $227,688.10. Following the completion of the sale, the director owned 51,803 shares in the company, valued at $12,159,718.19. The trade was a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 16,774 shares of company stock valued at $3,846,275. Company insiders own 0.58% of the company’s stock.

ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.

Read More

Receive News & Ratings for ResMed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc and related companies with MarketBeat.com's FREE daily email newsletter.